Results 131 to 140 of about 6,429 (163)
757. Optimised Oncolytic Herpes Simplex Virus for Cancer Treatment
Molecular Therapy, 2003 openaire +1 more source
Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy [PDF]
International Journal of Molecular Sciences, 2020 Oncolytic viruses are smart therapeutics against cancer due to their potential to replicate and produce the needed therapeutic dose in the tumor, and to their ability to self-exhaust upon tumor clearance. Oncolytic virotherapy strategies based on the herpes simplex virus are reaching their thirties, and a wide variety of approaches has been envisioned ...
Elisa Avitabile +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Herpes simplex virus oncolytic vaccine therapy in melanoma
Expert Opinion on Biological Therapy, 2010Advanced melanoma is a devastating disease with a five year survival for Stage IV disease of 10 - 20% and a median survival of 6 - 18 months depending on sub-stage. Current FDA approved therapies demonstrate limited response rates, few complete remissions and no proven survival benefit. New therapies are clearly needed. JSI/34.5-/47-/GM-CSF is a herpes
Yvonne Saenger, Howard Kaufman
exaly +3 more sources
Rethinking herpes simplex virus: the way to oncolytic agents
Reviews in Medical Virology, 2011SUMMARYOncolytic viruses infect, replicate in and kill cancer cells. HSV has emerged as a most promising candidate because it exerts a generally moderate pathogenicity in humans; it is amenable to attenuation and tropism retargeting; the ample genome provides space for heterologous genes; specific antiviral therapy is available in a worst case scenario.
CAMPADELLI, MARIA GABRIELLA +5 more
openaire +2 more sources
Characterization of an Oncolytic Herpes Simplex Virus Drug Candidate
Journal of Pharmaceutical Sciences, 2015The structural integrity and conformational stability of a genetically modified live, oncolytic herpes simplex virus (o-HSV) were investigated across a wide pH (5.5-8.0) and temperature (10°C-87.5°C) range. A combination of circular dichroism, intrinsic and extrinsic fluorescence, and static light scattering results was visualized using an empirical ...
Ozan S, Kumru +10 more
openaire +2 more sources
Oncolytic Herpes Simplex Virus Engineering and Preparation
2011Herpes simplex virus-1 (HSV-1) is an enveloped, double-stranded DNA virus that has been used with modification as an oncolytic virus against a number of tumor types. Modifications that make HSV-1 replication--conditional, i.e., selectively divide in replicating cells make it fulfill a prerequisite criteria for oncolytic viruses.
Pankaj K, Agarwalla, Manish K, Aghi
openaire +2 more sources
Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest
2019Herpes simplex virus (HSV) is one of the most extensively studied oncolytic virus platforms. The recent FDA approval of talimogene laherparepvec (T-VEC) has been accelerating translational research of oncolytic HSV (oHSV) as a promising therapeutic for refractory cancers such as glioblastoma, the deadliest primary malignancy in the brain.
Andranik, Kahramanian +2 more
openaire +2 more sources
Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2
Human Gene Therapy, 2019Oncolytic virotherapy is a new and safe therapeutic strategy based on the inherent cytotoxicity of oncolytic viruses and their ability to replicate and spread within tumors in a selective manner. In a previous study, a new type of oncolytic herpes simplex virus type 2 (oHSV-2, named OH2) was constructed to treat human cancers.
Yang, Wang +16 more
openaire +2 more sources
Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens
Current Cancer Drug Targets, 2018Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cells. Herpes simplex virus (HSV) is a promising agent for oncolytic virotherapy due to its broad cell tropism and the identification of mutations that favor its replication in tumor over normal cells.
Hideaki Tahara +2 more
exaly +3 more sources
Oncolytic virus therapy using genetically engineered herpes simplex viruses
Frontiers in Bioscience, 2002Genetically engineered, conditionally replicating herpes simplex viruses type 1 (HSV-1) are promising therapeutic agents for cancer. They can replicate in situ, spread, and exhibit oncolytic activity via a direct cytocidal effect. In addition, oncolytic HSV-1 can transfer and express foreign genes in host cells.
openaire +3 more sources